Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC Debt Repayment
Cash used to repay borrowings during the period.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment of $0 in Q1 FY2026
Q1 FY2026 debt repayment was $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (551.14K) | — |
Debt Repayment vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's FY2025 debt repayment of $0 is the 7th largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +100.0% is the highest of 3, against a peer median of +0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.17M | — | — | — | |
| FY2025 | $250K | — | — | — | |
| LTM Mar 2026 | $183K | — | — | — | |
| LTM Sep 2025 | $172.14K | — | — | — | |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | FY2025 | $135.17K | — | — | — |
COPLCopley Acquisition Corp | LTM Mar 2026 | $13.53K | — | — | — |
OACCOaktree Acquisition Corp. III Life Sciences | FY2025 | $0 | +100.0% | — | — |
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| FY2025 | $0 | +100.0% | — | — | |
| Peer median (excluding OACC) | $0 | +0.0% | — | — | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | 2.66K | 7.29M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | (629) | 0 |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 0 | (33.55K) |
| Other Working Capital | (629) | 0 |
| Other Non-Cash Items | (91.72K) | (7.71M) |
| Operating Cash Flow | (179) | (422.08K) |
| Capital Expenditures | (3) | 0 |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (191.99M) | 0 |
| Sales of Investments | 0 | 0 |
| Other Investing Activities | 0 | 500K |
| Investing Cash Flow | (191.99M) | 500K |
| Debt Repayment | (551.14K) | 0 |
| Common Stock Issued | 193.99M | 0 |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 193.44M | 0 |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | 1.36M | 77.92K |
| Free Cash Flow | (179) | (422.08K) |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.